Dear Colleagues:

The 1st International Urolithiasis Research Symposium held here in Indianapolis in November of 2006 was a remarkable success. The unique nature of the symposium emphasizing the latest developments in the field of urolithiasis created an exciting atmosphere resulting in robust interaction between the faculty and audience. A poster session was also well attended and of the highest quality. Proceedings of the meeting (including the poster session) was published creating a very useful document for urologists and basic science researchers interested in stone disease. It is, therefore, with great enthusiasm and anticipation that we announce and invite you to the 2nd International Urolithiasis Research Symposium here in Indianapolis April 17-18, 2008. We have once again compiled an outstanding faculty to address new findings in basic research on the pathogenesis of stone disease and recent advances in the treatment of urolithiasis. There will be an opportunity for researchers to submit abstracts for presentation in a poster session.

We hope that you will be able to join us in Indianapolis next Spring for an exciting and stimulating meeting.

Sincerely,

James E. Lingeman, M.D., FACS
Methodist Hospital Institute for Kidney Stone Disease
Co-Director, International Kidney Stone Institute

Andrew P. Evan, Ph.D.
Chancellor’s Professor
Department of Anatomy and Cell Biology
Indiana University School of Medicine
Co-Director, International Kidney Stone Institute
2nd International Urolithiasis Research Symposium
The Westin Hotel, Indianapolis, Indiana

Thursday, April 17, 2008

6:30-7:30 a.m. Registration and Continental Breakfast

7:30-7:35 a.m. Introduction to the meeting James E. Lingeman, M.D.
Indianapolis, Indiana

7:35-7:55 a.m. Pathogenesis of stone disease Elaine M. Worcester, M.D.
Chicago, Illinois

7:55-8:15 a.m. Surgical treatment of stone disease Glenn M. Preminger, M.D.
Durham, North Carolina

Session 1 Factors that regulate normal and abnormal mineralization: Session I
Moderators: Sharon Moe, M.D., Indianapolis, Indiana
David A. Bushinsky, M.D., Rochester, New York

8:15-8:30 a.m. Hypercalciuric bone disease Rajiv Kumar, M.D.
Rochester, Minnesota

8:40-8:55 a.m. Bone genes and other determinants of pathologic calcification in blood vessels Marc McKee, Ph.D.
Montreal, Canada

9:05-9:20 a.m. Bone genes in kidney of stone formers Andrew P. Evan, Ph.D.
Indianapolis, Indiana

9:30-9:45 a.m. Cell biology of thiazide bone effects Gerardo Gamba, M.D., Ph.D.
Mexico City, Mexico

9:55-10:15 a.m. Break

Session 2 Factors that regulate normal and abnormal mineralization: Session II
Moderators: Rajiv Kumar, M.D. Rochester, Minnesota
Joseph Bidwell, Ph.D., Indianapolis, Indiana

10:15-10:30 a.m. Bone proton receptor regulation of mineralization David A. Bushinsky, M.D.
Rochester, New York

10:40-10:55 a.m. Pyrophosphate transport and stones John Sayer, Ph.D.
Newcastle Upon Tyne, United Kingdom

11:05-11:20 a.m. FGF-23, Klotho and Leptin in regulation of mineral dynamics Orson W. Moe, M.D.
Dallas, Texas

11:30-11:45 a.m. Calcium sensing receptor in stone disease Steven C. Hebert, M.D.
New Haven, Connecticut

11:55 a.m.-12:40 p.m. Lunch

Session 3 Medullary and papillary cell biology
Moderators: Lise Bankir, Ph.D., Paris, France
Andrew P. Evan, Ph.D., Indianapolis, Indiana

12:40-12:55 p.m. IMCD cell biology—proton and urea transport Susan Wall, Ph.D.
Atlanta, Georgia

1:05-1:20 p.m. New animal model of interstitial plaque, OPN/THP knockout Xue-Ru Wu, M.D.
New York, New York

1:30-1:45 p.m. Papillary epithelial cells in stone disease — new cell line Hari K. Koul, Ph.D.
Denver, Colorado

1:55-2:10 p.m. Production of hyaluronan by interstitial cells Louise Rugheimer, MS.c
Uppsala, Sweden
2:20-2:35 p.m.  Hyaluronan and stone disease  
Marino Asselman, M.D.  
Rotterdam, The Netherlands

2:45-3:00 p.m.  Stones in idiopathic calcium oxalate stone disease are attached to sites of interstitial plaque  
Nicole L. Miller, M.D.  
Nashville, Tennessee

3:10-3:30 p.m.  Break

Session 4  
Ureteral stents and physiology
Moderators: Stephen Y. Nakada, M.D., Madison, Wisconsin  
Michael Grasso, III, M.D., New York, New York

3:30-3:45 p.m.  Implications of biofilm formation on urological devices  
Peter Cadieux, Ph.D.  
London, Canada

3:55-4:10 p.m.  Drug eluting stents: in vitro studies  
Ben H. Chew, M.D.  
Vancouver, Canada

4:20-4:35 p.m.  Drug eluting urological stents: fact or fiction  
John D. Denstedt, M.D.  
London, Canada

4:45-5:00 p.m.  Ureteral stents: new designs and materials  
Manoj Monga, M.D.  
Minneapolis, Minnesota

5:10-5:25 p.m.  Dynamic and static models for the assessment of biofilm and encrustation formation on urological materials  
Sean P. Gorman, Ph.D.  
Belfast, Ireland

5:35-5:50 p.m.  Ureteral stent coatings: what is here and what is coming?  
Hassan Razvi, M.D.  
London, Canada

6:30-8:30 p.m.  Reception/Poster Session

Friday, April 18, 2008

6:30-7:30 a.m.  Continental Breakfast

Session 5  Clinical biology of stone formers
Moderators: John R. Asplin, M.D., Chicago, Illinois  
David S. Goldfarb, M.D., New York, New York

7:30-7:45 a.m.  Circadian variations of stone risk  
Elaine M. Worcester, M.D.  
Chicago, Illinois

7:55-8:10 a.m.  Bariatric surgery and stone disease  
John C. Lieske, M.D.  
Rochester, Minnesota

8:20-8:35 a.m.  Uric acid and diabetes  
Naim M. Maalouf, M.D.  
Dallas, Texas

8:45-9:00 a.m.  Kidney stone morphology—implications for stone pathogenesis  
Michel Daudon, Ph.D.  
Paris, France

9:10-9:25 a.m.  Very long follow-up of treated stone patients  
Fredric L. Coe, M.D.  
Chicago, Illinois

9:35-9:55 a.m.  Break

Session 6  Progress in shock wave lithotripsy
Moderators: Lawrence A. Crum, Ph.D., Seattle, Washington  
R. John Honey, M.D., Toronto, Canada

9:55-10:10 a.m.  The advantage of a broad focal zone in SWL  
Robin O. Cleveland, Ph.D.  
Boston, Massachusetts

10:20-10:35 a.m.  Standards for lithotriptor performance  
Reiner Schultheiss, Ph.D.  
Illighausen, Switzerland

10:45-11:00 a.m.  The characteristics of broad and narrow focal zone lithotriptors  
Yuri Pishchalnikov, Ph.D.  
Indianapolis, Indiana
11:10-11:25 a.m.  Treatment protocols to reduce injury and improve stone breakage in SWL  
James A. McAteer, Ph.D.  
Indianapolis, Indiana

11:35-11:50 a.m.  Renal hemodynamics during SWL  
Rajash K. Handa, Ph.D.  
Indianapolis, Indiana

12:00-12:45 p.m.  Lunch

12:45-1:00 p.m.  Outcomes assessment in SWL  
David A. Tolley, M.D.  
Edinburgh, United Kingdom

1:10-1:25 p.m.  Determining the SW-treatment endpoint  
Michael R. Bailey, Ph.D.  
Seattle, Washington

1:35-1:50 p.m.  Real-time monitoring of lithotriptor performance  
Tim Leighton, Ph.D.  
Southampton, United Kingdom

2:00-2:15 p.m.  Perspective on lithotripsy adverse effects  
Thomas Knoll, M.D.  
Mannheim, Germany

2:25-2:40 p.m.  Long-term effects of SWL and PNL  
Amy E. Krambeck, M.D.  
Rochester, Minnesota

2:50-3:05 p.m.  Urolithiasis in space

3:15-3:45 p.m.  Meeting Summary: Pathogenesis of stone disease  
Fredric L. Coe, M.D.  
Chicago, Illinois

3:45-4:15 p.m.  Meeting Summary: Urologic aspects  
Margaret S. Pearle, M.D.  
Dallas, Texas

4:30 p.m.  Adjourn

ACKNOWLEDGMENT:
IKSI gratefully acknowledges the following for educational grants in support of this program:

Symposium Sponsor  
Boston Scientific

Faculty Dinner Sponsor  
Gyrus ACMI

Gold Level Sponsor  
Cook Urological

Silver Level Sponsors  
Applied Medical  
AST Advanced Shockwave Technology GmbH  
Direx Systems Corporation  
Lumenis  
Mission Pharmacal  
Olympus America, Inc.  
Quest Diagnostics

Bronze Level Sponsors  
Convergent Laser Technologies  
EMS Electro Medical Systems SA

SPONSORED BY:
CALL FOR ABSTRACTS
The submission of an abstract constitutes the author’s commitment to present the abstract as accepted. Abstracts must be written in English and, if accepted, presented in English. All accepted abstracts will be presented in an unmoderated poster session.

Size: The size of the abstract is limited to 400 words. This includes title, body of abstract, tables, and graphics.

Title: The title should clearly define the topic and contain no abbreviations.

Authors: List the primary author’s full name, followed by the other authors’ names. Spell out completely the names of all authors using full first name, middle initial, and last name. The presenting author’s name should be underlined.

Body of Abstract: The abstract should be informative and detailed. The body must contain four separate paragraphs: 1) Introduction and Objectives; 2) Methods; 3) Results; and 4) Conclusions. It is NOT acceptable to state that “The results will be discussed.” Inclusion of specific data is helpful to the reviewers. Standard abbreviations may be used as follows: on first use, spell out the full term and follow with the abbreviation in parentheses. Proprietary names of drugs are not allowed; generic names must be used.

Source of Funding: Grant support must be indicated.

Conflict of Interest and Disclosure Statement: All authors must disclose conflicts of interest.

Key Words: Authors must select up to three key word entries that describe the subject of the abstract.

All abstracts should be submitted via e-mail to csprunger@clarian.org.

COURSE DESCRIPTION
The symposium will be a comprehensive review of new knowledge in the pathogenesis of stone disease, including bariatric surgery. Further, new developments in ureteral stenting and advances in shock wave lithotripsy will be presented.

OBJECTIVES
- Review the relationship between bone disease and stone disease
- Examine the latest developments in endourology from both a basic science and clinical perspective
- Describe the mechanisms of shock wave action in stone breakage, the tissue response to treatment, and strategies to improve outcomes
- Outline recent developments in the medical therapy of ureteral stone management and new developments with novel ureteral stents
- Compare the relationships among various systemic disorders and nephrolithiasis

MEETING REGISTRATION
Meeting registration must be completed online at http://cme.medicine.iu.edu by March 15, 2008. After March 15, 2008, please register at the door. Registration for all attendees is $350 U.S. The registration fee includes: course materials, breakfasts, breaks, lunches, and a reception/poster session.

Cancellations must be received in writing by March 28, 2008 and will be subject to a $75 processing fee for this course. No refunds will be given after March 28, 2008.

CME CREDITS
Accreditation Statement
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The Indiana University School of Medicine designates this educational activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Note: While it offers CME credit hours, this activity is not intended to provide extensive training or certification in the field.

WESTIN HOTEL RESERVATIONS
For hotel reservations, please call the Westin Hotel Indianapolis directly at 317/262-8100 or 1-800-WESTIN-1. Be sure to mention that you will be attending the 2nd International Urolithiasis Research Symposium to receive the special group rate of $175 U.S. per night for a single room. This rate is exclusive of applicable state and local taxes. The group rate cannot be guaranteed after March 17, 2008. Reservations must be guaranteed with a major credit card. You can also make your hotel reservation by visiting our web site at www.iksi.org.

LOCATION OF THE WESTIN
The Westin Indianapolis is located at 50 South Capital Avenue, Indianapolis, Indiana. The phone number is 1-800-WESTIN-1 or 317/262-8100.